Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

European shares fell on Friday following a U.S. Federal Reserve interest rate cut. Drugmaker Novo Nordisk's obesity pill data ...

An experimental obesity pill being developed by Ozempic-maker Novo Nordisk showed only limited additional weight loss when taken in higher doses compared to the lowest dose tested in a mid-stage ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market ...

Novo Nordisk's (NOVOb.CO), opens new tab shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market ...

But in the headline trial results released on Friday, the once-daily pill resulted in only 6.5% weight loss after 16 weeks. Novo Nordisk shares were down 4.8% at 1407 GMT, at their lowest level in ...

The future holds promise for robots to actively collaborate in diverse aspects of human endeavor, transforming industries ...